HE4 (WFDC2) gene overexpression promotes ovarian tumor growth

Scientific Reports

Volumn 4, Issue SREP03574, 2014, Pages

  Moore, Richard G ^a   Hill, Emily K ^a   Horan, Timothy ^a   Yano, Naohiro ^a   Kim, KyuKwang ^a   MacLaughlan, Shannon ^b   Lambert Messerlian, Geralyn ^a   Tseng, YiTang Don ^a   Padbury, James F ^a   Craig Miller, M ^a   Lange, Thilo S ^a,c   Singh, Rakesh K ^a  

^a BROWN UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PROTEIN; WFDC2 PROTEIN, HUMAN;

ANIMAL; ARTICLE; BLOOD; CELL DIVISION; DISEASE MODEL; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOUSE; OVARY TUMOR; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MICE; OVARIAN NEOPLASMS; PROTEINS;

EID: 84891758710     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03574     Document Type: Article

References (37)

1. Kirchhoff, C., Habben, I., Ivell, R. & Krull, N. Amajor human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 45, 350-357 (1991).
2. Bingle, L., Singleton, V. & Bingle, C. D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 21, 2768-2773 (2002). (Pubitemid 34478335)
3. Drapkin, R. et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65, 2162-2169 (2005). (Pubitemid 40490123)
4. Galgano, M. T., Hampton, G. M. & Frierson, H. F. Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19, 847-853 (2006). (Pubitemid 43780455)
5. Hellström, I. et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63, 3695-6700 (2003).
6. Ono, K. et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60, 5007-5011 (2000).
7. Welsh, J. B. et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci 98, 1176-1181 (2001). (Pubitemid 32121206)
8. Huhtinen, K. et al. Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts. Br J Cancer 100, 1315-1319 (2009).
9. Moore, R. G. et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 203, 228. e1-6 (2010).
10. Moore, R. G. et al. A novel multiple marker bioassay utilizing HE4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass. Gyn Oncol 112, 40-46 (2009).
11. Van Gorp, T. et al. HE4 and CA 125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 104, 863-870 (2011).
12. Montagnana, M. et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 49, 521-525 (2011).
13. Molina, R. et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol 32, 1087-1095 (2011).
14. Li, J. et al. HE4 (WFDC2) Promotes tumor growth in endometrial cancer cell lines. Int J Mol Sci 14, 6026-6043 (2013).
15. Oliver, T. G. et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24, 837-852 (2010).
16. Sayer, R. A. et al. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gyn Oncol 96, 355-361 (2005). (Pubitemid 40127134)
17. Beck, E. P. Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer tissue. Gyn Oncol 53, 196-201 (1994). (Pubitemid 24177044)
18. Osada, R. et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38, 1310-1320 (2007). (Pubitemid 47247486)
19. Nakai, H., Watanabe, Y., Ueda, H. & Hoshiai, H. Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer. Cancer Lett 251, 164-167 (2007). (Pubitemid 46589775)
20. Birner, P. M., Schindle, A., Obermair, G., Breitenecker, G. & Oberhuber, G. Expression of hypoxia-inducible factor 1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7, 1661-1668 (2001). (Pubitemid 32708633)
21. Moore, R. G., Brown, A. K., Miller, M. C. et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108, 402-408 (2008). (Pubitemid 351174295)
22. Bingle, L. et al. WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respiratory Research 7, 61 (2006).
23. Wei, H. et al. Silencing of the TGF-β1Gene Increases the Immunogenicity of Cells from Human Ovarian Carcinoma. J Immunother 35, 267-275 (2012).
24. Lu, R. et al. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 419, 274-280 (2012).
25. Allison, S. J. Fibrosis: HE4-a biomarker and target in renal fibrosis. Nature Reviews Nephrology 9, 124 (2013).
26. LeBleu, V. S. et al. Identification of human epididymis protein-4 as a fibroblastderived mediator of fibrosis. Nature Medicine 19, 227-231 (2013).
27. Braicu, E. I. et al. Preoperative HE4 overexpresssion in plasma predicts surgical outcome in primary ovarian cancer patients. Results from the OVCAD study. Gynecol Oncol 128, 245-251 (2013).
28. Kang, S. et al. Serum HE4 level is an independent risk factor of surgical outcome and prognosis of epithelial ovarian cancer. Gyn Oncol 120, S2-S133 (2011).
29. Georgakopoulos, P., Mehmood, S., Akalin, A. & Shroyer, K. R. Immunohistochemical localization of HE4 in benign, borderline and malignant lesion of the ovary. Int J of Gyn Path 31, 517-523 (2012).
30. Zhai, W. & Comai, L. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol Cell Biol 20, 5930-5938 (2000). (Pubitemid 30613042)
31. Cavanaugh, A. H. et al. Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 374, 177-180 (1995).
32. Arabi, A. et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 7, 303-310 (2005). (Pubitemid 40331132)
33. Maihle, N. J. et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat and Res 107, 247-258 (2002).
34. Gotlieb, W. H. et al. Insulin-like growthfactor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 100, 389-396 (2006). (Pubitemid 43075275)
35. Spannuth, W. A. et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 124, 1045-1053 (2009).
36. Oladipupo, S. et al. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc Natl Acad Sci 108, 13264-13269 (2011).
37. Moore, R. G. et al. Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model. PLoS ONE 7, e34443 (2012).